Hand Foot Syndrome Market Report 2026

The hand foot syndrome market size has grown strongly in recent years. It will grow from $0.52 billion in 2025 to $0.55 billion in 2026 at a compound annual growth rate (CAGR) of 6.3%. The growth in the historic period can be attributed to increasing use of chemotherapy regimens, rising incidence of drug-induced dermatological side effects, expansion of oncology treatment programs, improved awareness of supportive cancer care, availability of topical therapeutic products.

The hand foot syndrome market size is expected to see strong growth in the next few years. It will grow to $0.7 billion in 2030 at a compound annual growth rate (CAGR) of 6.4%. The growth in the forecast period can be attributed to increasing demand for supportive oncology care solutions, rising investments in dermatology-oncology crossover treatments, expansion of homecare-based symptom management, growing focus on improving patient quality of life, increasing development of advanced topical formulations. Major trends in the forecast period include increasing development of targeted topical therapies, rising focus on patient-centric symptom management, growing adoption of combination treatment approaches, expansion of supportive dermatology care protocols, enhanced emphasis on treatment compliance.

The rising incidence of cancer is expected to accelerate the growth of the hand foot syndrome market in the coming years. Cancer is a condition marked by uncontrolled cell proliferation and the potential to spread to other parts of the body. The increase in cancer cases is attributed to factors such as aging populations, lifestyle modifications, environmental influences, and improved diagnostic and detection techniques. As cancer incidence rises, the use of chemotherapy also increases, which subsequently elevates the occurrence of hand-foot syndrome as a common treatment-related side effect. For example, in August 2024, Macmillan Cancer Support, a UK-based charitable organization supporting individuals affected by cancer, reported that more than 3 million people in the UK were living with cancer. This figure is expected to grow to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Therefore, the growing burden of cancer is driving the expansion of the hand foot syndrome market.

The growing demand for personalized treatments is anticipated to further propel the growth of the hand foot syndrome market. Personalized treatments involve medical therapies customized to a patient’s unique genetic makeup, environmental exposures, and lifestyle factors to enhance effectiveness and reduce adverse effects. Demand for such treatments is increasing due to advances in genetic and molecular research, greater awareness of individualized healthcare approaches, and recognition that tailored therapies often deliver better outcomes with fewer side effects than conventional standardized treatments. In the context of hand-foot syndrome, personalized treatment strategies enable customized prevention and management based on disease severity, symptom profile, and chemotherapy regimen, helping to alleviate discomfort while allowing patients to continue cancer therapy. For instance, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that in 2023 the U.S. Food and Drug Administration approved 16 new personalized treatments for rare disease patients, up from six approvals in 2022. Therefore, the increasing emphasis on personalized care is contributing to the growth of the hand foot syndrome market.

In June 2024, AstraZeneca Plc, a UK-based pharmaceutical company, acquired Fusion Pharmaceuticals Inc. for $2.5 billion. This strategic acquisition is intended to strengthen AstraZeneca’s oncology portfolio by adding advanced radiopharmaceutical assets such as FPI-2265, expanding its research, development, and manufacturing capabilities, and accelerating the transition toward targeted cancer therapies, while also enhancing its presence in Canada. Fusion Pharmaceuticals Inc. is a Canada-based biotechnology company focused on the development of next-generation radiopharmaceuticals as precision oncology treatments.

Major companies operating in the hand foot syndrome market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis International AG, Fresenius Kabi AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., UCB Pharma SA, Eisai Co. Ltd.

Asia-Pacific was the largest region in the hand food syndrome market in 2025. The regions covered in the hand foot syndrome market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hand foot syndrome market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the hand foot syndrome market by increasing costs of imported active pharmaceutical ingredients, dermatological formulations, packaging materials, and specialized medical creams. Oncology treatment centers in North America and Europe are most affected due to reliance on imported supportive care products, while Asia-Pacific faces cost pressures on pharmaceutical exports. These tariffs are raising treatment costs and affecting product availability. However, they are also promoting domestic pharmaceutical production, regional formulation development, and broader access to locally manufactured supportive care treatments.

The hand foot syndrome market research report is one of a series of new reports that provides hand foot syndrome market statistics, including hand foot syndrome industry global market size, regional shares, competitors with a hand foot syndrome market share, detailed hand foot syndrome market segments, market trends and opportunities, and any further data you may need to thrive in the hand foot syndrome industry. This hand foot syndrome market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Hand foot syndrome, also known as palmar-plantar erythrodysesthesia, is a condition induced by chemotherapy or certain medications. It causes redness, swelling, pain, and peeling of the skin on the palms of the hands and the soles of the feet. In severe cases, blisters and ulcerations can develop, interfering with routine daily activities.

The main treatments for hand foot syndrome include systemic and topical therapies. Systemic treatments consist of medications that work throughout the body to relieve symptoms and reduce the risk of complications. These treatments are applied across various medical fields, including oncology and dermatology, and are used in healthcare settings such as hospitals, clinics, and homecare environments.

The hand foot syndrome market consists of revenues earned by entities providing services such as treatments, therapies, and supportive care services for managing symptoms and complications of the condition. The market value includes the value of related goods sold by the service provider or included within the service offering. The hand foot syndrome market also includes sales of pharmaceutical drugs, topical treatments, and medical devices used to alleviate symptoms and manage the condition. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.